<SEC-DOCUMENT>0001179110-17-009798.txt : 20170629
<SEC-HEADER>0001179110-17-009798.hdr.sgml : 20170629
<ACCEPTANCE-DATETIME>20170629190459
ACCESSION NUMBER:		0001179110-17-009798
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170627
FILED AS OF DATE:		20170629
DATE AS OF CHANGE:		20170629

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BeiGene, Ltd.
		CENTRAL INDEX KEY:			0001651308
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		C/O MOURANT OZANNES CORPORATE SERVICES
		STREET 2:		94 SOLARIS AVENUE, CAMANA BAY
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108
		BUSINESS PHONE:		13459494123

	MAIL ADDRESS:	
		STREET 1:		C/O MOURANT OZANNES CORPORATE SERVICES
		STREET 2:		94 SOLARIS AVENUE, CAMANA BAY
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Peterson Amy C.
		CENTRAL INDEX KEY:			0001682735

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37686
		FILM NUMBER:		17939902

	MAIL ADDRESS:	
		STREET 1:		C/O MOURANT OZANNES CORPORATE SERVICES
		STREET 2:		94 SOLARIS AVENUE
		CITY:			CAMANA BAY, GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>FORM 4 -
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-06-27</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001651308</issuerCik>
        <issuerName>BeiGene, Ltd.</issuerName>
        <issuerTradingSymbol>BGNE</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001682735</rptOwnerCik>
            <rptOwnerName>Peterson Amy C.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MOURANT OZANNES CORPORATE SERVICES,</rptOwnerStreet1>
            <rptOwnerStreet2>94 SOLARIS AVENUE</rptOwnerStreet2>
            <rptOwnerCity>CAMANA BAY, GRAND CAYMAN</rptOwnerCity>
            <rptOwnerState>E9</rptOwnerState>
            <rptOwnerZipCode>KY1-1108</rptOwnerZipCode>
            <rptOwnerStateDescription>CAYMAN ISLANDS</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>CMO, Immuno-oncology</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Share Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.49</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2017-06-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1016178</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-06-26</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1016178</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1016178</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.  The exercise price is equal to 1/13 of the closing price of our American Depositary Shares (&quot;ADSs&quot;) on the date of grant, as each ADS represents 13 ordinary shares.</footnote>
        <footnote id="F2">The options vest over a four-year period as follows: 25% on the first anniversary of the date of grant, with the remaining shares vesting in 36 equal successive monthly installments on the last day of each month thereafter.  Unvested options are subject to accelerated vesting upon certain termination events following a change in control.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Scott A. Samuels, as Attorney-in-Fact</signatureName>
        <signatureDate>2017-06-29</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>ex24amy.txt
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
LIMITED POWER OF ATTORNEY
The undersigned hereby constitutes and appoints each of Scott A. Samuels,
Howard Liang, Qing Nian and Riley Lovendale, signing singly, and with
full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

(1)  execute for and on behalf of the undersigned, in the
undersigned's capacity as officer and/or director of
BeiGene, Ltd. and/or its subsidiaries (the "Company"),
from time to time the following U.S. Securities and
Exchange Commission ("SEC") forms: (i) Form ID, including
any attached documents, to effect the assignment of codes
to the undersigned to be used in the transmission of
information to the SEC using the EDGAR System; (ii)
Form 3, Initial Statement of Beneficial Ownership of
Securities, including any attached documents; (iii)
Form 4, Statement of Changes in Beneficial Ownership
of Securities, including any attached documents;
(iv) Form 5, Annual Statement of Beneficial Ownership
of Securities in accordance with Section 16(a) of
the Securities Exchange Act of 1934, as amended,
and the rules thereunder, including any attached documents;
(v) Schedule 13D and (vi) amendments of each thereof,
in accordance with the Securities Exchange Act of 1934,
as amended, and the rules thereunder, including any attached documents;

(2)  do and perform any and all acts for and on behalf
of the undersigned which may be necessary or desirable
to complete and execute any such Form 3, 4 or 5,
Schedule 13D or any amendment(s) thereto, and timely
file such form(s) with the SEC and any securities
exchange, national association or similar authority; and

(3)  take any other action of any type whatsoever
in connection with the foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by,
the undersigned, it being understood that the documents
executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall
be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact,
acting singly, full power and authority to do and
perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of
any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might
or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause
to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned
acknowledges that the foregoing attorneys-in-fact,
in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities
to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended.
The undersigned hereby agrees to indemnify the
attorneys-in-fact and the Company from and against
any demand, damage, loss, cost or expense arising
from any false or misleading information provided
by the undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force
and effect until the undersigned is no longer
required to file such forms with respect to the
undersigned's holdings of and transactions in
securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
This Power of Attorney supersedes any prior
power of attorney in connection with the
undersigned's capacity as an officer and/or director
of the Company. This Power of Attorney shall
expire as to any individual attorney-in-fact
if such attorney-in-fact ceases to be an
executive officer of, or legal counsel to,
the Company.

IN WITNESS WHEREOF, the undersigned has
caused this Power of Attorney to be executed
as of June 7, 2017.

/s/ Amy Peterson
Name: AMY PETERSON




</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
